Publications

cemka > Publications

Classer les publications sur l'année

  • Économie de la santĂ©

    Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

    DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F

    Oncology ; 72:248-254

  • Économie de la santĂ©

    A model of the public health impact of improved treatment persistence in post-meopausal osteoroposis in France

    COTTE FE, CORTET B, LAFUMA A, AVOUAC B, HASNAOUI AE, FADELLONE P, POUCHAIN D, ROUX C, GAUDIN AF

    Joint Bone Spine ; 31

  • BiomĂ©trie et Analyses de bases de donnĂ©es/SNDS

    A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy

    DENIS PH, LAFUMA A, KHOSHNOOD B, MIMAUD V, BERDEAUX G

    Curr Med Res Opin ; 23(3):601-608

  • Pharmaco-EpidĂ©miologie

    A benefit for renal function after early switch to liposomal amphotericin B from conventional formulation in empirical antifungal treatment

    ISNARD F, TILLEUL P, LAPORTE JF, CHEVALLIER P, PIGNEUX A, LAFUMA A, MAHI L, DERAY G

    Nephrol Dial Transplant ; 22(10):3090-3091

  • SantĂ© publique

    Evaluation of a screening programme for diabetic retinopathy (DODIA study).

    AUBERT JP, MASSIN P, AUDRAN G, BEN MEHIDI A, BERNIT B, BOUÉE S, BOUHASSIRA M, BOUROVITCH JC, ERGINAY A, ESCHWEGE E, JAMET M, MARRE M, NOUGAIRÈDE M, TCHERNY-LESSENOT S

    Rev Prat. ; 57(11):1203-1209

  • Pharmaco-EpidĂ©miologie

    StratĂ©gie diagnostique de l’infection par le VHC en mĂ©decine gĂ©nĂ©rale : Etats des lieux, nature des obstacles rencontrĂ©s – Etude GYMKHANA 1 (2Ăšme partie)

    AUBERT JP, BOUEE S, BENTATA M, COMPAGNON M, ELGHOZI B, LIVROZET JM, MECHALI D, PERDRIEAU F, PY AM, ROZEMBAUM W, TAULERA O, WAJSBROT A

    Rev Prat - Médecine Générale ; 20(726/727):386-391

  • Pharmaco-EpidĂ©miologie

    Seroprevalence of Varicella in the French Population

    KHOSHNOOD B, DEBRUYNE M, LANCON F, EMERY C, FAGNANI F, DURAND I, FLORET D

    Pediatr Infect Dis J ; 25(1):41-44

  • Pharmaco-EpidĂ©miologie

    Prevalence of visual impairment in relation to the number of ophtalmologists in a given area : a nationwide approach

    LAFUMA A, BREZIN A, FAGNANI F, MESBAH M, BERDEAUX G

    Health and Quality of Life Outcomes ; 4(34)

  • Économie de la santĂ©

    Nonmedical economic consequences attribuables to visual impairment nation-wide approach in France

    LAFUMA A, BREZIN A, FAGNANI F, MIMAUD V, MESBAH M, BERDEAUX G

    Eur J Health Econom ; 7(3):158-164

  • SantĂ© publique

    Management of innovative medicines in hospitals: an international comparison

    LAFUMA A, TILLEUL P

    EJHPP Practice ; 12(1):26-27

  • SantĂ© publique

    La nécessaire clarification de la place des réseaux de santé

    SANNINO N, DONIO V

    FiliÚres & Réseaux 2 Santé ; (7):44-45

  • Pharmaco-EpidĂ©miologie

    Human papillomavirus testing with a liquid-based system : feasibility and comparison with reference diagnoses

    BERGERON C, CAS F, FAGNANI F, DIDAILLER-LAMBERT F, POVEDA JD

    Acta Cytol ; 50(1):16-22

  • Économie de la santĂ©

    Evaluation of non-medical costs associated with visual impairment in four European countries – France, Italy, Germany and the UK

    LAFUMA A, BREZIN A, LAPATRIELLO S, HIEKE K, HUTCHINSON J, MIMAUD V, BERDEAUX G

    Pharmacoeconomics ; 24(2):193-205

  • Économie de la santĂ©

    Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries

    BOUEE S, LAFUMA A, FAGNANI F, MEUNIER PJ, REGINSTER JY

    Rheumatol Int ; 26(12):1063-72

  • Économie de la santĂ©

    Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France

    TILLEUL P, LAFUMA A, COLIN X, OZIER Y

    Clin Appl Thromb Hemost ; 12(4):473-484